Table 2

Baseline characteristics in RA and controls

Age (years), mean±SD28959.4±11.328062.9±11.9*
Females, n (%)289230 (80)280153 (55)***
Height (m), mean±SD2891.67±0.082801.69±0.1**
Weight (kg), mean±SD28974.9±13.828076.9±14.3 ns
BMI (kg/m²), mean±SD28927.0±4.528026.8±4.0 ns
Fat mass (%), mean±SD28938.8±7.428035.3±7.2***
RF seropositivity, n (%)289229 (79)
ACPA positive, n (%)289200 (87)
DAS28CRP, median (IQR)2852.1 (1.3)
CRP (mg/L), median (IQR)2742.2 (3.5)
Disease duration (years), median (IQR)2899 (12)
HAQ (0–3), median (IQR)2890.5 (0–1.3)
Medication current, n (%)280
 Jak inhibitors, n (%)22 (8)
 cDMARDs, n (%)190 (68)
 bDMARDs, n (%)130 (46)
 Glucocorticoids, n (%)147 (53)
Cumulative dose prednisone equivalent (g), median (IQR)27510.0 (21)
  • *p<0.01, **p<0.001, ***p<0.0001.

  • ACPA, anticitrullinated peptide antibodies; bDMARDS, biological disease-modifying antirheumatic drugs; BMI, body mass index; cDMARDS, conventional disease-modifying antirheumatic drugs; CRP, C reactive protein; DAS28CRP, Disease Activity Score of 28 joints including C reactive protein; HAQ, Health Assessment Questionnaire; ns, non-significant; RA, rheumatoid arthritis; RF, rheumatoid factor.